RANIBIZUMAB
ranibizumab 2.3 mg/0.23 mL injection, 0.23 mL vial
RANIBIZUMAB (13165X)
13165X
Body System:
Manner of administration:Injection
Restriction 17395
Indication: Proliferative diabetic retinopathy (PDR) and/or Diabetic macular oedema (DMO)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $786.69 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||